Vanadium toxicity

Background

• Vanadium toxicity is a rare poisoning caused by exposure to vanadium compounds, most commonly through occupational inhalation of vanadium pentoxide (V₂O₅) dust or, far less commonly, through ingestion of vanadium salts.
• Inhalation toxicity primarily manifests as respiratory irritation and occupational asthma ("boilermaker's bronchitis"), while ingestion of large amounts can cause acute multiorgan failure and death.
• Vanadium (V) is a transition metal found ubiquitously in the environment in mineral ores and fossil fuels
• Common oxidation states: V³⁺, V⁴⁺ (vanadyl), V⁵⁺ (vanadate) — pentavalent (V⁵⁺) compounds are the most toxic
• Toxicologically significant compounds:
  • Vanadium pentoxide (V₂O₅) — most common occupational exposure (dust/fume)
  • Ammonium metavanadate (NH₄VO₃) — used in laboratory and industrial settings
  • Sodium metavanadate (NaVO₃) and sodium orthovanadate (Na₃VO₄)
  • Vanadyl sulfate (VOSO₄) — sold as a dietary/bodybuilding supplement
• Sources of exposure:
  • Occupational: boiler cleaning (oil-fired), vanadium refining, steel/alloy manufacturing, fossil fuel combustion, catalyst production
  • Dietary supplements: vanadyl sulfate used by athletes/bodybuilders for purported anabolic and insulin-mimetic effects (doses up to 60 mg/day)
  • Environmental: air pollution near power plants; contaminated groundwater (rare)
  • Intentional: extremely rare; only two fatal ingestion cases in the world literature
• Vanadium pentoxide is ~100% absorbed by inhalation but only 0.1-1% absorbed orally
• 60% of absorbed vanadium is excreted renally within 24 hours
• Vanadium has insulin-mimetic properties and has been studied as a diabetes treatment; GI side effects are dose-limiting

Mechanism of toxicity

• Generates reactive oxygen species (ROS) → lipid peroxidation, glutathione depletion, oxidative stress
• Inhibits Na⁺/K⁺-ATPase, phosphotyrosine phosphatases, ribonuclease, and other enzymes
• In massive ingestion, may inhibit cellular respiratory processes similar to other mitochondrial poisons
• Direct mucosal irritant to respiratory and GI epithelium
• Pentavalent vanadium (vanadate) is reduced intracellularly to tetravalent vanadyl, with redox cycling generating additional free radicals

Clinical features

Inhalation exposure (most common)

• "Boilermaker's bronchitis" — the classic occupational syndrome
• Upper airway:
  • Rhinitis, nasal congestion, epistaxis
  • Pharyngitis, sore throat
  • Nasal mucosal ulceration (chronic exposure)
• Lower airway:
  • Cough, wheezing, chest tightness, dyspnea
  • Bronchospasm, occupational asthma
  • Bronchial hyperreactivity (may persist weeks after exposure)
  • Decreased FEV₁
  • Chemical bronchopneumopathy (severe/massive exposure)
• Characteristic finding: "green tongue" — greenish discoloration of the tongue from local vanadium deposition; indicates significant dust exposure but is not a sign of systemic poisoning
• Systemic symptoms with heavy inhalation exposure:
  • Metallic taste
  • Headache, fatigue, tremor
  • Conjunctivitis, lacrimation

Oral ingestion (rare)

• Low-dose (supplements, <14 mg): generally well tolerated; possible mild GI irritation
• Moderate dose (≥14 mg): nausea, vomiting, abdominal cramps, diarrhea
  • Most patients develop tolerance to GI effects with continued exposure
• Massive ingestion (grams): extremely rare; reported features include:
  • Severe GI symptoms (nausea, vomiting, profuse diarrhea, abdominal pain)
  • Hypoglycemia (insulin-mimetic effects; glucose 0.2 g/L reported in fatal case)
  • Acute kidney injury
  • Respiratory distress (widespread tissue asphyxia)
  • Multiorgan failure and death
  • Symptom latency of approximately 12 hours before rapid clinical deterioration

Dermal/ocular exposure

• Concentrated vanadium chloride or oxide solutions cause chemical burns
• Eye contact with vanadium pentoxide dust causes conjunctivitis, corneal irritation
• Skin sensitization is extremely rare

Chronic exposure

• Persistent cough, wheezing, bronchial hyperreactivity
• Possible bronchitis and asthma
• Hematologic: microcytic erythrocytosis has been observed in animal studies (decreased hematocrit, hemoglobin, MCV)
• No confirmed increased cancer risk in humans from occupational exposure; IARC has not classified vanadium

Differential diagnosis

Acute ingestion

• Iron toxicity (similar GI + metabolic acidosis picture)
• Arsenic poisoning (similar GI onset)
• Caustic ingestion
• Hypoglycemia (other causes)
• Acute gastroenteritis

Toxic gas exposure

• Carbon monoxide toxicity
• Chemical weapons
• Cyanide toxicity
• Dichloromethane toxicity
• Hydrocarbon toxicity
• Hydrogen sulfide toxicity
• Inhalant abuse
  • Difluoroethane toxicity
• Methane toxicity
• Smoke inhalation injury
• Ethylene dibromide toxicity

Evaluation

Workup

• Detailed occupational and exposure history — most critical step; identify compound, route, duration, concentration
• Pulmonary function testing: spirometry (FEV₁, FVC) — for inhalation exposure; may show obstructive pattern
• Chest radiograph: generally normal in occupational exposure; may show infiltrates in massive inhalation
• Labs (for significant oral ingestion):
  • BMP (renal function, electrolytes, blood glucose — monitor for hypoglycemia)
  • Hepatic function panel
  • CBC (anemia, reticulocyte count)
  • Lactate, ABG
  • Urinalysis (proteinuria, hematuria)
• Vanadium levels:
  • 24-hour urine vanadium — best marker of recent exposure; ACGIH Biological Exposure Index is 50 μg/g creatinine at end of shift
  • Serum vanadium — elevated acutely (normal: ~1 μg/L; fatal case: 6,220 μg/L)
  • Hair/nail analysis for chronic exposure assessment
  • Note: seafood does not significantly elevate vanadium levels (unlike arsenic)
• ECG: in massive ingestion (monitor for metabolic effects)

Diagnosis

• Inhalation: clinical diagnosis based on occupational history + respiratory symptoms + green tongue
• Ingestion: clinical diagnosis based on history + GI symptoms + characteristic metabolic findings (hypoglycemia, renal failure); confirmed by elevated urine or serum vanadium levels
• Green tongue is pathognomonic for vanadium dust exposure but does not indicate systemic poisoning

Management

Inhalation exposure

• Remove from exposure — move patient to fresh air immediately
• Decontamination: remove contaminated clothing; wash skin with soap and water; irrigate eyes with copious water if exposed
• Bronchospasm: inhaled beta-2 agonists (albuterol); systemic corticosteroids if severe
• Supplemental oxygen as needed
• Supportive care: most cases of occupational inhalation resolve with removal from exposure and bronchodilators
• Monitor pulmonary function; bronchial hyperreactivity may persist for weeks

Oral ingestion

• GI decontamination:
  • Gastric lavage if presenting early after large ingestion
  • Activated charcoal — no specific data for vanadium, but may be considered if presenting within 1-2 hours
  • Whole-bowel irrigation may be considered for large ingestions
• Aggressive IV fluid resuscitation
• Monitor and correct blood glucose — hypoglycemia may be severe (insulin-mimetic effect); treat with IV dextrose
• Supportive care for renal failure, respiratory failure, metabolic derangements
• Hemodialysis — may be indicated for acute kidney injury; vanadium clearance by dialysis is uncertain

Chelation therapy

• No chelation therapy has proven clinical efficacy in human vanadium poisoning
• Agents studied (primarily in animal models):
  • Ascorbic acid (vitamin C): most promising agent; reduces pentavalent vanadate to less toxic tetravalent vanadyl; also functions as an antioxidant and ROS scavenger; suggested as the safest and most effective pharmacologic option
  • CaNa₂EDTA: enhances urinary vanadium excretion in animals; carries risk of nephrotoxicity
  • Tiron (4,5-dihydroxybenzene-1,3-disulfonate): partially effective in animal studies
  • DMSA, DMPS: potential chelating antidotes; limited data
  • Deferoxamine (DFOA): limited efficacy
• In practice, ascorbic acid (high-dose IV vitamin C) is the most reasonable adjunctive therapy based on available evidence, though it has not been validated in human clinical trials

Antioxidant therapy

• Vitamin C: high-dose (1-2 g IV); both chelating and antioxidant properties
• Vitamin E: adjunctive antioxidant (limited evidence)
• Rationale: vanadium toxicity is heavily mediated by oxidative stress; antioxidants may mitigate cellular injury

Disposition

• Mild inhalation exposure (respiratory symptoms only, stable):
  • Observe in ED for 4-6 hours after removal from exposure
  • Discharge if symptoms improving and pulmonary function acceptable
  • Occupational medicine follow-up; workplace exposure assessment
  • Return precautions for worsening respiratory symptoms (may be delayed hours to days)
• Significant inhalation exposure (severe bronchospasm, respiratory distress):
  • Admit for observation and treatment; monitor pulmonary function
• Oral ingestion of small supplement dose:
  • Observe; symptomatic management of GI complaints; discharge if stable
• Massive oral ingestion:
  • ICU admission — continuous monitoring
  • Serial glucose, renal function, ABGs
  • Anticipate rapid deterioration after ~12-hour latency period
  • High mortality in the rare case of massive salt ingestion
• All intentional ingestions: psychiatric evaluation mandatory prior to discharge
• Contact Poison control (1-800-222-1222 in the US) for all cases

See Also

• Metal fume fever
• Iron toxicity
• Arsenic poisoning
• Copper sulfate poisoning
• Hypoglycemia

External Links

• ATSDR — Toxicological Profile for Vanadium: Health Effects (2012)
• Oxid Med Cell Longev — Protective Effects of Dietary Antioxidants against Vanadium-Induced Toxicity (2020)
• ATSDR — Vanadium Medical Management Guidelines
• Haz-Map — Vanadium Pentoxide